<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119557</url>
  </required_header>
  <id_info>
    <org_study_id>17239</org_study_id>
    <secondary_id>J1P-MC-KFAC</secondary_id>
    <nct_id>NCT04119557</nct_id>
  </id_info>
  <brief_title>A Study of LY3471851 in Participants With Psoriasis</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety and side effects of
      LY3471851 when given by injection just under the skin to participants with psoriasis. The
      study will last up to 48 weeks and may include up to 23 visits to the study center.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">April 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Study Completion (up to Week 48)</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3471851</measure>
    <time_frame>Postdose on Day 1 through Day 14</time_frame>
    <description>PK: AUC of LY3471851</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Trough Concentrations (Ctrough) of LY3471851</measure>
    <time_frame>Week 12</time_frame>
    <description>PK: Ctrough of LY3471851</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3471851</measure>
    <time_frame>Postdose on Day 1 through Day 14</time_frame>
    <description>PK: Cmax of LY3471851</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>LY3471851</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3471851 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3471851</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3471851</arm_group_label>
    <other_name>NKTR-358</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a confirmed diagnosis of psoriasis for at least 6 months

          -  Have active psoriasis plaques according to study- specific criteria

          -  Be willing and able to undergo skin biopsies

        Exclusion Criteria:

          -  Have received certain topical medications for psoriasis within 14 days prior to
             baseline

          -  Have received certain systemic medications for psoriasis within 4 weeks prior to
             baseline

          -  Have received LY3471851 previously
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Dermatology and Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>760-203-3839</phone>
    </contact>
    <investigator>
      <last_name>Stacy R. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-6800</phone>
    </contact>
    <investigator>
      <last_name>Neal D Bhatia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Academic Dermatology Centers</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-324-2110</phone>
    </contact>
    <investigator>
      <last_name>Francisco A Kerdel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-264-2155</phone>
    </contact>
    <investigator>
      <last_name>Seth Benjamin Forman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Dermatology Specialists</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 404-939-9220</phone>
    </contact>
    <investigator>
      <last_name>Jamie Debra Weisman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-516-5030</phone>
    </contact>
    <investigator>
      <last_name>Scott A Fretzin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Sciences</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>502-451-9000</phone>
    </contact>
    <investigator>
      <last_name>Leon H Kircik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialist</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>502-585-9059</phone>
    </contact>
    <investigator>
      <last_name>Cindy E Owen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derm Center</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>248-244-8448</phone>
    </contact>
    <investigator>
      <last_name>George J Murakawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Dermatology PC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-721-5565</phone>
    </contact>
    <investigator>
      <last_name>Craig L Leonardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, Inc</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>603-319-8863</phone>
    </contact>
    <investigator>
      <last_name>Abel Jarell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Remington-Davis, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>614-487-2560</phone>
    </contact>
    <investigator>
      <last_name>Michelle C Chambers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-606-3900</phone>
    </contact>
    <investigator>
      <last_name>Jarad Levin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Company Inc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-563-7330</phone>
    </contact>
    <investigator>
      <last_name>Lawrence C. Parish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermDox Centers for Dermatology</name>
      <address>
        <city>Sugarloaf</city>
        <state>Pennsylvania</state>
        <zip>18249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>570-459-0029</phone>
    </contact>
    <investigator>
      <last_name>Stephen M Schleicher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rodgers Dermatology</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-704-2400</phone>
    </contact>
    <investigator>
      <last_name>Timothy G Rodgers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/psoriasis/KFAC#?postal=</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

